Carnitine and Depression

Ting Liu; Kunhong Deng; Ying Xue; Rui Yang; Rong Yang; Zhicheng Gong; Mimi Tang

doi:10.3389/fnut.2022.853058

Carnitine and Depression

Front Nutr. 2022 Mar 14:9:853058. doi: 10.3389/fnut.2022.853058. eCollection 2022.

Authors

Ting Liu^{1

2}, Kunhong Deng³, Ying Xue^{1

2}, Rui Yang^{1

2}, Rong Yang^{1

2}, Zhicheng Gong^{1

2}, Mimi Tang^{1

2}

Affiliations

¹ Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
² National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Institute for Rational and Safe Medication Practices, Central South University, Changsha, China.
³ Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.

Abstract

Depression has become one of the most common mental diseases in the world, but the understanding of its pathogenesis, diagnosis and treatments remains insufficient. Carnitine is a natural substance that exists in organisms, which can be synthesized in vivo or supplemented by intake. Relationships of carnitine with depression, bipolar disorder and other mental diseases have been reported in different studies. Several studies show that the level of acylcarnitines (ACs) changes significantly in patients with depression compared with healthy controls while the supplementation of acetyl-L-carnitine is beneficial to the treatment of depression. In this review, we aimed to clarify the effects of ACs in depressive patients and to explore whether ACs might be the biomarkers for the diagnosis of depression and provide new ideas to treat depression.

Keywords: acylcarnitines; bipolar disorder; carnitine; depression; schizophrenia.

Publication types

Review